Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane for Cognitive Function in Frontal Brain Damage
NCT04252261Phase 2Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in frontal lobe syndrome (FLS) comparing Sulforaphane with Placebo (2 arms). Primary endpoint: Changes from baseline cognitive tests scores at 3 months. Status: unknown.
02
Drugs
sulforaphane
03
Conditions
frontal lobe syndrome (FLS)
Beyond the preview
Go deeper on NCT04252261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252261.